CleanSpace Holdings' Growth Story Meets Regulatory Delays

Strong FY25 growth gave way to repeated guidance downgrades as new respirator certifications were delayed and key markets softened, though fund managers say the profitability thesis remains intact.

31 Aug 2026 · 3 min read

CleanSpace Holdings, a producer of innovative powered air purifying respirators for industrial workplace safety, delivered a strong FY25 with positive EBITDA and 25 percent revenue growth, before regulatory delays for new loose-fitting respirator products and softening US demand forced repeated guidance downgrades, from 25 percent to 15 percent and eventually to low single-digit growth.

A strong FY25 built on regulatory pipeline optimism

Jencay Capital described CleanSpace as a producer of innovative powered air purifying respirators for industrial workplace safety, enjoying a strong second half, producing positive EBITDA and free cash flow alongside 25 percent revenue growth for FY25, with an R&D pipeline containing exciting product additions awaiting regulatory clearance.

Growth disappoints as regulatory delays and external shocks bite

Jencay Capital said revenue growth for the four months prior to the AGM was a bit disappointing at 13 percent year on year, though the company remained optimistic growth would reaccelerate once two exciting products in its R&D pipeline received regulatory clearance. Merewether Capital said CleanSpace reported revenue up 10 percent to $10.1 million and an operating loss that improved 23 percent to negative $345,000, though it was a weaker than expected result, with regulatory issues seeing revenue growth come in under guidance and full-year expectations reset from 25 percent revenue growth to 15 percent, with optimism for a better second half maintaining the investment thesis of a high-margin manufacturer inflecting into profitability. Jencay Capital said revenue growth for the first half at 10 percent was below expectations, held back by the impact of the US government shutdown on US sales and the temporary closure of an Indonesian mine, one of the company's biggest customers, describing CleanSpace as one of the biggest detractors in the quarter.

It was a weaker than expected result from CSX with some regulatory issues seeing revenue growth come in under guidance and leading to full year expectations reset from 25% revenue growth to 15%. While disappointing there is optimism for a better second half that maintains the investment thesis of a high margin manufacturer inflecting into profitability.

— Merewether Capital, Monthly Report, February 2026

A second downgrade to low single-digit growth

Merewether Capital said CleanSpace Holdings downgraded revenue guidance from around 15 percent to low single-digit growth, with the weaker than expected result driven by softening demand in key markets, particularly the US, alongside delays in certification of new loose-fitting respirators that don't require fit testing and can be worn with facial hair. Despite the miss on revenue expectations, costs have been well managed, and the underlying thesis remains intact, prompting the fund to hold its position.

Cleanspace Holdings downgraded their revenue guidance from ~15% to 'low single digit' growth, driven by a softening of demand in key markets (particularly the US) as well as delays in the certification of new loose-fitting respirators. Despite the miss, costs have been well managed and the underlying thesis remains intact for CSX, so we have held our position.

— Merewether Capital, Investor Update, May 2026

What fund managers say they are watching next is regulatory clearance for the new loose-fitting respirators that don't require fit testing, whether US demand stabilises after the government shutdown impact, resolution of customer concentration risk given the Indonesian mine customer, and whether the high-margin manufacturer inflecting-into-profitability thesis holds up despite repeated guidance downgrades.